Collagen Receptor Implicated in Immune Exclusion

An antibody drug directed at the collagen receptor DDR1 helps to mitigate immune exclusion in a mouse model of triple-negative breast cancer, allowing T cells to flood in and slow tumor progression. A startup company called Parthenon Therapeutics has launched to advance the therapy into clinical development.